Trial Profile
Phase I/II Randomised, Double- Blind, Multi-centre Study to Assess the Efficacy of AZD2281 When Given in Combination With Paclitaxel in the 1st or 2nd Line Treatment of Patients With Metastatic Triple Negative Breast Cancer
Status:
Completed
Phase of Trial:
Phase I/II
Latest Information Update: 29 Dec 2021
Price :
$35
*
At a glance
- Drugs Olaparib (Primary) ; Paclitaxel
- Indications Advanced breast cancer; Triple negative breast cancer
- Focus Adverse reactions; Therapeutic Use
- Sponsors AstraZeneca
- 05 Mar 2018 Status changed from active, no longer recruiting to completed.
- 29 Nov 2017 Planned End Date changed from 29 Dec 2017 to 28 Dec 2018.
- 30 Dec 2016 Planned End Date changed from 1 Dec 2016 to 1 Dec 2017.